A
AEON
Aeon Biopharma
0.2760
-0.0340-10.97%After Hours: 0.2875 +0.0115 +4.17%19:36 10/09 EDT
OPEN/PREV CLOSE0.3101/0.3100
TODAY RANGE0.2760-0.3189
VOL1.63M
MARKET CAP13.77M
52 WEEK RANGE0.1772-1.450
AVG VOL (3M)8.62M
% TURNOVER3.14%
TURNOVER--
P/E (TTM)-0.0770
% RANGE12.97%
EPS(TTM)-3.5840
P/E(FORWARD)-0.3680
P/B-0.4727
BVPS-0.5839
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP6.49M
SHARES OUTSTANDING49.88M
NEXT EARNINGS--
FREE FLOAT23.51M
LOT SIZE1
EX-DATE02/26/2025
News
Press Releases
Financial Reports
Profile
Benzinga·10/02 21:05
12 Health Care Stocks Moving In Friday's After-Market Session
NASDAQ·10/02 13:06
AEON Biopharma Consensus Price Target Raised by 16.39% to $1.81
Benzinga·10/01 18:10
Apple To $355? Here Are 10 Top Analyst Forecasts For Thursday
Dow Jones·10/01 16:19
AEON Biopharma Is Maintained at Buy by Lake Street
Benzinga·10/01 16:10
Lake Street Maintains Buy on AEON Biopharma, Raises Price Target to $2
TipRanks·10/01 12:46
Aeon Biopharma price target raised to $2 from $1 at Lake Street
NASDAQ·09/30 18:49
Biotech Stocks Surge - NIVF +124%, CNTB +124%, SGMT +9%, VBIO +12%, AEON
Benzinga·09/30 17:06
12 Health Care Stocks Moving In Wednesday's Intraday Session
TipRanks·09/30 13:16
Lake Street Remains a Buy on AEON Biopharma (AEON)
NASDAQ·09/30 12:37
AEON Gains FDA Feedback On ABP-450 Biosimilar Pathway
TipRanks·09/30 12:34
AEON Biopharma advances ABP-450 biosimilar development strategy
NASDAQ·09/30 12:30
AEON Clarifies ABP-450 Biosimilar Development Plan
TipRanks·09/30 12:15
Aeon FDA Type 2b meeting feedback clarifies development plan for ABP-450
Benzinga·09/14 17:06
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga·09/11 17:06
12 Health Care Stocks Moving In Friday's Intraday Session